Lite Strategy stock posts $16 million Q1 profit as buybacks cut shares

Lite Strategy reported fiscal 2027 first-quarter results on Tuesday, November 10, with net income of 16.0 million US dollars for the period ended September 30, 2026. The company said the result was driven mainly by the remeasurement of its Litecoin treasury, while share repurchases reduced outstanding shares by 6.8 percent. The figures were reported by Markets Insider, which carried the GlobeNewswire release.

Buybacks And Lower Cash Use

Lite Strategy repurchased approximately 2.2 million shares at an average price of 1.08 US dollars during the quarter. The company said cumulative repurchases since the program began reached approximately 18 percent of shares outstanding by September 30.

General and administrative expenses fell 24 percent to 2.4 million US dollars, while net cash used in operating activities declined 52 percent to 2.2 million US dollars from the prior-year quarter. The covered-call program generated approximately 130,000 US dollars in premium proceeds during the period.

Litecoin Treasury Remains Central

Lite Strategy held 751,798 Litecoin at September 30, with a fair value of 50.5 million US dollars. The holding included 64,700 Litecoin pledged as collateral for covered-call options. Cash and cash equivalents stood at 4.3 million US dollars, total assets at 58.4 million US dollars and total liabilities at 1.7 million US dollars. The company reported no outstanding debt.

LITS stock was quoted at 0.99 US dollars at 22:00 CET on Wednesday, November 11, in after-hours trading. The quote is stated without a daily comparison because no compatible Xetra closing price was established.

Fiscal 2027 Priorities

During October, Lite Strategy repurchased another 825,181 shares at a weighted-average price of 1.27 US dollars. Management said its priorities for the remainder of fiscal 2027 include expanding institutional investor relations, developing activity around the Litecoin ecosystem and evaluating selective acquisitions and strategic partnerships.

The company also continues to evaluate its pharmaceutical assets, including the oral CDK9 inhibitor voruciclib and zandelisib, for potential out-licensing or sale. Lite Strategy was formerly MEI Pharma and retains these assets alongside its digital-asset treasury strategy.

The wider US equity market can be followed in the S&P 500.

More news and analyses on Lite Strategy stock.